Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial

doi:10.1016/j.annonc.2021.03.205

Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial

科研成果: 期刊稿件 › 文章 › 同行评审

源语言	英语
页（从-至）	896-905
页数	10
期刊	Annals of Oncology
卷	32
期	7
DOI	https://doi.org/10.1016/j.annonc.2021.03.205
出版状态	已出版 - 7月 2021
已对外发布	是

!!!ASJC Scopus Subject Areas

血液学
肿瘤学

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

访问文件

10.1016/j.annonc.2021.03.205

其它文件与链接

引用此

@article{dc2e861f28b24149b957fdbcba7074ee,

title = "Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial",

keywords = "androgen receptor pathway inhibitor, circulating tumor DNA (ctDNA), plasma cell-free DNA, prostate cancer, taxane chemotherapy",

note = "Publisher Copyright: {\textcopyright} 2021 European Society for Medical Oncology",

year = "2021",

month = jul,

doi = "10.1016/j.annonc.2021.03.205",

language = "English",

volume = "32",

pages = "896--905",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "7",

}

TY - JOUR

T1 - Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer

T2 - a multicentre, randomised, open-label, phase II trial

PY - 2021/7

Y1 - 2021/7

KW - androgen receptor pathway inhibitor

KW - circulating tumor DNA (ctDNA)

KW - plasma cell-free DNA

KW - prostate cancer

KW - taxane chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=85105110200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85105110200&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2021.03.205

DO - 10.1016/j.annonc.2021.03.205

M3 - Article

C2 - 33836265

AN - SCOPUS:85105110200

SN - 0923-7534

VL - 32

SP - 896

EP - 905

JO - Annals of Oncology

JF - Annals of Oncology

IS - 7

ER -

Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial

!!!ASJC Scopus Subject Areas

联合国可持续发展目标

访问文件

其它文件与链接

指纹

引用此